文献速递神经核医学

淀粉样蛋白PET在神经退行性疾病影像学中的作用:综述

The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review.
PubMed 文献 · J Nucl Med · 2022-01-01

淀粉样蛋白PET已获美国食品药品监督管理局、欧洲药品管理局等监管机构批准用于临床,是阿尔茨海默病诊断的关键工具,可无创检测定义该病的核心神经病理特征淀粉样斑块。随着aducanumab在美国加速获批用于治疗阿尔茨海默病所致的轻度认知障碍和轻度痴呆,淀粉样蛋白PET的临床使用预计将增加。本综述深入分析临床、病理与影像学的关联,比较其他可用生物标志物,并回顾淀粉样蛋白PET在临床试验和临床效用研究中的应用。

要点

  • 淀粉样蛋白PET可无创检测淀粉样斑块,是阿尔茨海默病诊断的关键工具。
  • 淀粉样蛋白病理也可见于认知未受损的老年人和其它神经退行性疾病患者。
  • aducanumab在美国加速获批后,淀粉样蛋白PET的临床使用预计将增加。

核心结论

  • 本综述旨在提供淀粉样蛋白PET在神经退行性疾病中应用的最新概述。

研究设计与样本

  • 综述:提供淀粉样蛋白PET在神经退行性疾病中应用的深入分析,包括临床、病理与影像学关联、与其他生物标志物的比较,以及在临床试验和临床效用研究中的应用。

主要发现

  • 淀粉样蛋白PET是阿尔茨海默病诊断的关键工具,可无创检测定义该病的核心神经病理特征淀粉样斑块。
  • 淀粉样蛋白病理也可见于认知未受损的老年人和其它神经退行性疾病患者。

关键数值与推荐

  • 淀粉样蛋白PET已获美国食品药品监督管理局、欧洲药品管理局及全球其它监管机构批准用于临床。
  • aducanumab在美国获加速批准用于治疗阿尔茨海默病所致的轻度认知障碍和轻度痴呆。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Imaging of amyloid deposition using PET has been available in research studies for 2 decades and has been approved for clinical use by the U.S. Food and Drug Administration, the European Medicines Agency, and other regulatory agencies around the world. Amyloid PET is a crucial tool for the diagnosis of Alzheimer disease, as it allows the noninvasive detection of amyloid plaques, a core neuropathologic feature that defines the disease. The clinical use of amyloid PET is expected to increase with recent accelerated approval in the United States of aducanumab, an antiamyloid monoclonal antibody, for the treatment of mild cognitive impairment and mild dementia due to Alzheimer disease. However, amyloid pathology can also be found in cognitively unimpaired older adults and in patients with other neurodegenerative disorders. The aim of this review is to provide an up-to-date overview of the application of amyloid PET in neurodegenerative diseases. We provide an in-depth analysis of the clinical, pathologic, and imaging correlates; a comparison with other available biomarkers; and a review of the application of amyloid PET in clinical trials and clinical utility studies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Chapleau M, Iaccarino L, Soleimani-Meigooni D, et al. The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. J Nucl Med. 2022. PMID: 35649652. doi:10.2967/jnumed.121.263195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。